1
|
Crisafulli S, Luxi N, Sultana J, Fontana
A, Spagnolo F, Giuffrida G, Ferraù F, Gianfrilli D, Cozzolino A,
Cristina De Martino M, et al: Global epidemiology of acromegaly: A
systematic review and meta-analysis. Eur J Endocrinol. 185:251–263.
2021.PubMed/NCBI View Article : Google Scholar
|
2
|
Esposito D, Ragnarsson O, Johannsson G and
Olsson DS: Prolonged diagnostic delay in acromegaly is associated
with increased morbidity and mortality. Eur J Endocrinol.
182:523–531. 2020.PubMed/NCBI View Article : Google Scholar
|
3
|
Dąbrowska AM, Tarach JS, Kurowska M and
Nowakowski A: Thyroid diseases in patients with acromegaly. Arch
Med Sci. 10:837–845. 2014.PubMed/NCBI View Article : Google Scholar
|
4
|
Vargas-Ortega G, Romero-Gameros CA,
Rendón-Macias ME, Balcázar-Hernández L, Sosa-Eroza E, Mercado M, de
Los Monteros-Sánchez ALE, Pérez-Aguilar B, Paredes-Manjarrez C,
Reyes-Olhagaray FB, et al: Risk factors associated with thyroid
nodular disease in acromegalic patients: A case-cohort study in a
tertiary center. Growth Horm IGF Res. 60-61(101431)2021.PubMed/NCBI View Article : Google Scholar
|
5
|
Natchev E, Vandeva S, Kovatcheva R,
Kirilov G, Kalinov K and Zacharieva S: Thyroid gland changes in
patients with acromegaly. Arch Endocrinol Metab. 64:269–275.
2020.PubMed/NCBI View Article : Google Scholar
|
6
|
Tirosh A and Shimon I: Complications of
acromegaly: Thyroid and colon. Pituitary. 20:70–75. 2017.PubMed/NCBI View Article : Google Scholar
|
7
|
Manavela M, Vigovich C, Danilowicz K, Juri
A, Miechi L, Fernandez Valoni V and Bruno OD: Thyroid autoimmune
disorders in patients with acromegaly. Pituitary. 18:912–915.
2015.PubMed/NCBI View Article : Google Scholar
|
8
|
Franco JS, Amaya-Amaya J and Anaya JM:
Thyroid disease and autoimmune diseases. In: Autoimmunity: from
bench to bedside. Anaya JM, Shoenfeld Y, Rojas-Villarraga A, et
al (eds). El Rosario University Press, Bogota, pp537-562,
2013.
|
9
|
Stanciu M, Bera LG, Popescu M, Grosu F and
Popa FL: Hashimoto's thyroiditis associated with thyroid adenoma
with Hürthle cells-case report. Rom J Morphol Embryol. 58:241–248.
2017.PubMed/NCBI
|
10
|
Pokhrel B and Bhusal K: Graves' Disease.
In: StatPearls [Internet]. StatPearls Publishing, Treasure Island,
FL, pp4-5, 2022.
|
11
|
Bahn RS: Graves' ophthalmopathy. N Engl J
Med. 362:726–738. 2010.PubMed/NCBI View Article : Google Scholar
|
12
|
Gardner DG and Shoback D: Greenspan's
Basic and Clinical Endocrinology. 10th edition. McGraw Hill
Medical, New York, NY, pp69-120, 2017.
|
13
|
Halse J and Haugen HN: Calcium and
phosphate metabolism in acromegaly. Acta Endocrinol (Copenh).
94:459–467. 1980.PubMed/NCBI View Article : Google Scholar
|
14
|
Mosekilde L and Christensen MS: Decreased
parathyroid function in hyperthyroidism: Interrelationships between
serum parathyroid hormone, calcium-phosphorus metabolism and
thyroid function. Acta Endocrinol (Copenh). 84:566–575.
1977.PubMed/NCBI View Article : Google Scholar
|
15
|
Tessler FN, Middleton WD, Grant EG, Hoang
JK, Berland LL, Teefey SA, Cronan JJ, Beland MD, Desser TS, Frates
MC, et al: ACR thyroid imaging, reporting and data system
(TI-RADS): White paper of the ACR TI-RADS Committee. J Am Coll
Radiol. 14:587–595. 2017.PubMed/NCBI View Article : Google Scholar
|
16
|
Bartalena L, Kahaly GJ, Baldeschi L, Dayan
CM, Eckstein A, Marcocci C, Marinò M, Vaidya B and Wiersinga WM:
EUGOGO†. The 2021 European Group on Graves' orbitopathy (EUGOGO)
clinical practice guidelines for the medical management of Graves'
orbitopathy. Eur J Endocrinol. 185:G43–G67. 2021.PubMed/NCBI View Article : Google Scholar
|
17
|
Bel Lassen P, Kyrilli A, Lytrivi M and
Corvilain B: Graves' disease, multinodular goiter and subclinical
hyperthyroidism. Ann Endocrinol (Paris). 80:240–249.
2019.PubMed/NCBI View Article : Google Scholar
|
18
|
Persani L: Clinical review: Central
hypothyroidism: Pathogenic, diagnostic, and therapeutic challenges.
J Clin Endocrinol Metab. 97:3068–3078. 2012.PubMed/NCBI View Article : Google Scholar
|
19
|
Jehle AW, Forgo J, Biber J, Lederer E,
Krapf R and Murer H: IGF-I and vanadate stimulate Na/Pi-cotransport
in OK cells by increasing type II Na/Pi-cotransporter protein
stability. Pflugers Arch. 437:149–154. 1998.PubMed/NCBI View Article : Google Scholar
|
20
|
Xie T, Tian P, Wu S, Zhang X, Liu T, Gu Y,
Sun C and Hu F: Serum phosphate: Does it more closely reflect the
true state of acromegaly? J Clin Neurosci. 71:26–31.
2020.PubMed/NCBI View Article : Google Scholar
|
21
|
Yalin GY, Tanrikulu S, Gul N, Uzum AK,
Aral F and Tanakol R: Utility of baseline serum phosphorus levels
for predicting remission in acromegaly patients. J Endocrinol
Invest. 40:867–874. 2017.PubMed/NCBI View Article : Google Scholar
|
22
|
Di Cerbo A, Pezzuto F and Di Cerbo A:
Growth hormone and insulin-like growth factor 1 affect the severity
of Graves' disease. Endocrinol Diabetes Metab Case Rep.
2017:17–0061. 2017.PubMed/NCBI View Article : Google Scholar
|
23
|
Ribeiro F, Ruas L, Júnior A, Sousa A,
Araújo A, Mwambire J, Jesus A, Bussuan R, Sá L and Arbex A: Graves'
disease and Marine Lenhart syndrome: A rare clinical presentation.
Health. 11:1169–1176. 2019.
|
24
|
Shen G, Cui F, Huang R and Kuang A:
Graves' disease following radioiodine therapy for toxic adenoma:
Clinical case report. Medicine (Baltimore).
96(e8550)2017.PubMed/NCBI View Article : Google Scholar
|
25
|
Nygaard B, Knudsen JH, Hegedüs L, Scient
AV and Hansen JE: Thyrotropin receptor antibodies and Graves'
disease, a side-effect of 131I treatment in patients with nontoxic
goiter. J Clin Endocrinol Metab. 82:2926–2930. 1997.PubMed/NCBI View Article : Google Scholar
|
26
|
Nygaard B, Faber J, Veje A, Hegedüs L and
Hansen JM: Transition of nodular toxic goiter to autoimmune
hyperthyroidism triggered by 131I therapy. Thyroid. 9:477–481.
1999.PubMed/NCBI View Article : Google Scholar
|
27
|
Lazarus JH: Epidemiology of Graves'
orbitopathy (GO) and relationship with thyroid disease. Best Pract
Res Clin Endocrinol Metab. 26:273–279. 2012.PubMed/NCBI View Article : Google Scholar
|
28
|
Coutu B, Alvarez DA, Ciurej A, Moneymaker
K, White M, Zhang C and Drincic A: Extraocular muscle enlargement
in growth hormone-secreting pituitary adenomas. AJNR Am J
Neuroradiol. 43:597–602. 2022.PubMed/NCBI View Article : Google Scholar
|
29
|
Ramos-Leví AM and Marazuela M: Bringing
cardiovascular comorbidities in acromegaly to an update. How should
we diagnose and manage them? Front Endocrinol (Lausanne).
10(120)2019.PubMed/NCBI View Article : Google Scholar
|
30
|
Prisant LM, Gujral JS and Mulloy AL:
Hyperthyroidism: A secondary cause of isolated systolic
hypertension. J Clin Hypertens (Greenwich). 8:596–599.
2006.PubMed/NCBI View Article : Google Scholar
|
31
|
Colao A, Auriemma RS, Lombardi G and
Pivonello R: Resistance to somatostatin analogs in acromegaly.
Endocr Rev. 32:247–271. 2011.PubMed/NCBI View Article : Google Scholar
|
32
|
Puig-Domingo M, Resmini E, Gomez-Anson B,
Nicolau J, Mora M, Palomera E, Martí C, Halperin I and Webb SM:
Magnetic resonance imaging as a predictor of response to
somatostatin analogs in acromegaly after surgical failure. J Clin
Endocrinol Metab. 95:4973–4978. 2010.PubMed/NCBI View Article : Google Scholar
|
33
|
Ezzat S, Caspar-Bell GM, Chik CL, Denis
MC, Domingue MÈ, Imran SA, Johnson MD, Lochnan HA, Grégoire Nyomba
BL, Prebtani A, et al: Predictive markers for postsurgical medical
management of acromegaly: A systematic review and consensus
treatment guideline. Endocr Pract. 25:379–393. 2019.PubMed/NCBI View Article : Google Scholar
|
34
|
Katznelson L, Laws ER Jr, Melmed S,
Molitch ME, Murad MH, Utz A and Wass JA: Endocrine Society.
Acromegaly: An endocrine society clinical practice guideline. J
Clin Endocrinol Metab. 99:3933–3951. 2014.PubMed/NCBI View Article : Google Scholar
|
35
|
van der Lely AJ, Biller BM, Brue T,
Buchfelder M, Ghigo E, Gomez R, Hey-Hadavi J, Lundgren F, Rajicic
N, Strasburger CJ, et al: Long-term safety of pegvisomant in
patients with acromegaly: Comprehensive review of 1288 subjects in
ACROSTUDY. J Clin Endocrinol Metab. 97:1589–1597. 2012.PubMed/NCBI View Article : Google Scholar
|
36
|
Fukami M, Suzuki E, Igarashi M, Miyado M
and Ogata T: Gain-of-function mutations in G-protein-coupled
receptor genes associated with human endocrine disorders. Clin
Endocrinol. 88:351–359. 2018.PubMed/NCBI View Article : Google Scholar
|